Lancet Infectious Diseases最新文献

{"title":"WHO prequalifies tools for relapsing malaria","authors":"Timothy Jesudason","doi":"10.1016/s1473-3099(25)00102-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00102-1","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"130 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143518084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1","authors":"Lu Zhang, Amy Kempf, Inga Nehlmeier, Nianzhen Chen, Metodi V Stankov, Christine Happle, Alexandra Dopfer-Jablonka, Georg M N Behrens, Markus Hoffmann, Stefan Pöhlmann","doi":"10.1016/s1473-3099(25)00113-6","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00113-6","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"32 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Infect Dis 2025; 25: 312–24","authors":"","doi":"10.1016/s1473-3099(25)00098-2","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00098-2","url":null,"abstract":"<em>Sengupta A, Ray A, Upadhyay AD, et al. Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis.</em> Lancet Infect Dis <em>2025; <strong>25:</strong> 312–24</em>—In table 2 of this Article, the <em>I</em>² value in the penultimate column for NTM lung disease should have been 89·5%. In the penultimate paragraph of the Results, the second sentence should have read “Higher proportions of patients with post-tuberculosis lung disease (–0·213 [–0·382 to –0·044]…”. These corrections have been made to the online version as of Feb 26, 2025, and the printed version is correct.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"85 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143518079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic granulomatous invasive fungal rhinosinusitis mimicking meningioma","authors":"Ling Aye, Weidong Zhao, Daniel Faden, Qing Wang, Yurong Gu, Liping Zhu, Dehui Wang","doi":"10.1016/s1473-3099(24)00809-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00809-0","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>The patient provided written consent for the publication of this Clinical Picture. LA, WZ, and DF contributed equally and share first authorship. DW conceptualised the Clinical Picture. LA wrote the original draft. LA, DF, QW, YG, WZ, and DW contributed to review and editing of the manuscript. LA, WZ, LZ, and DW participated in the care of the patient and evaluated the pathological examination. LA and WZ selected and prepared radiography and microscopy images. LA, WZ, LZ, DF, and DW developed</section></section><section><section><h2>Declaration of interests</h2>We declare no competing interests.</section></section>","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"33 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143518088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of the Mycetoma Activity and Severity clinical Scale (MASS): an international Delphi study","authors":"David J Chandler, Gail Davey, Roderick J Hay, Ahmed Fahal","doi":"10.1016/s1473-3099(24)00808-9","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00808-9","url":null,"abstract":"Mycetoma is a chronic, subcutaneous infection that causes local tissue destruction, leading to deformity, disability, and social stigma. Safe and effective treatments for mycetoma are urgently needed; however, there is no systematic measure that allows objective clinical assessment of disease severity and activity, which makes it difficult to accurately assess the effectiveness of treatments and draw comparisons between studies. A Delphi study was conducted, involving a panel of 23 mycetoma experts from five continents, to establish consensus on the structure, wording, and content of a clinical scoring system for mycetoma. Three rounds of anonymous surveys were conducted between August, 2023 and May, 2024. Consensus was defined as 65–85% agreement and strong consensus if 85% or higher. The final version of the Mycetoma Activity and Severity clinical Scale (MASS) consisted of 20 items, 14 pertaining to disease severity and six to disease activity, grouped into objective clinical features, patient-reported measures, and investigations. Consensus was achieved for 19 of the 20 items, and a strong consensus for 14. The MASS is the first clinical scoring system for mycetoma derived from a consensus approach and will facilitate accurate evaluation of treatment response if adopted into routine clinical practice by health-care workers across mycetoma-endemic regions. The MASS will also serve an important function as a research tool for use in prospective clinical studies and comparative drug trials.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"51 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143518076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global cholera resurgence—a preventable tragedy","authors":"Vijay Shankar Balakrishnan","doi":"10.1016/s1473-3099(25)00101-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00101-x","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"21 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143518081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing act: public health's delicate dance | Caitlin Rivers, Crisis averted: the hidden science of fighting outbreaks, Viking Press USA (2024), p. 320, £26·99, ISBN: 978-0593490792","authors":"Cahal McQuillan","doi":"10.1016/s1473-3099(25)00149-5","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00149-5","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"15 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social workers and neglected tropical diseases | Muhammed Jabir, Anoop C Choolayil, Social work with populations vulnerable to neglected tropical diseases: evidence and insights from India, Springer (2024), p. 96, £44·99, ISBN: 978-3031689963","authors":"Sanjeet Bagcchi","doi":"10.1016/s1473-3099(25)00148-3","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00148-3","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial","authors":"Ghady Haidar, Steven Thomas, Paul Loubet, Ross I Baker, Thomas Benfield, Jim Boonyaratanakornkit, Sasisopin Kiertiburanakul, Alfred H J Kim, Erin E Longbrake, Jean-Michel Molina, Roger Paredes, David Tucker, Alison Uriel, Julia Weinmann-Menke, Anastasia A Aksyuk, Lindsay E Clegg, Alexander Currie, Haitao Yang, Karin Flyrin, Michael Gibbs, Nawal Al Kaabi","doi":"10.1016/s1473-3099(24)00804-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00804-1","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Sipavibart is an anti-spike monoclonal antibody that neutralises SARS-CoV-2 with exceptions, including Phe456Leu-containing variants (eg, KP.2* and KP.3*). This trial assessed sipavibart efficacy and safety for prevention of symptomatic COVID-19 in participants who are immunocompromised.&lt;h3&gt;Methods&lt;/h3&gt;In this ongoing, double-blind, international, phase 3 trial, we enrolled participants who were immunocompromised and aged 12 years or older at 197 hospitals, university health centres, and clinical trial units in 18 countries. Participants were randomly allocated 1:1 to a sipavibart group (intramuscular sipavibart 300 mg on days 1 and 181) or a comparator group (tixagevimab 300 mg–cilgavimab 300 mg on day 1 and placebo on day 181 or placebo on days 1 and 181), stratified by previous COVID-19 vaccination and infection status and use of tixagevimab–cilgavimab. The primary efficacy outcomes were symptomatic COVID-19 caused by any variant or symptomatic COVID-19 caused by non-Phe456Leu-containing variants within 181 days of dosing, assessed in the SARS-CoV-2-negative set, comprising all participants without a positive RT-PCR test for SARS-CoV-2 at baseline and who received at least one trial intervention dose. Safety outcomes for adverse events were assessed 90 days following the first dose and for serious adverse events throughout the study in the safety analysis set (ie, all participants who received at least one injection of sipavibart or comparator). This study is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT05648110&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;.&lt;h3&gt;Findings&lt;/h3&gt;Participants were screened from March 31 to Oct 27, 2023; 3349 participants (56·8% female) were randomly assigned: 1674 to the sipavibart group (five no first dose; 1669 sipavibart) and 1675 to the comparator group (nine no first dose; 1105 tixagevimab–cilgavimab and 561 placebo). Within 181 days of dosing, 122 (7·4%) of 1649 participants in the sipavibart group and 178 (10·9%) of 1631 participants in the comparator group had symptomatic COVID-19 due to any variant (relative risk reduction [RRR] 34·9% [97·5% CI 15·0 to 50·1]; p=0·0006), 54 (3·3%) participants in the sipavibart group and 90 (5·5%) participants in the comparator group had symptomatic COVID-19 due to non-Phe456Leu-containing variants (RRR 42·9% [95% CI 19·9 to 59·3]; p=0·0012), and 47 (2·9%) participants in the sipavibart group and 64 (3·9%) participants in the comparator group had symptomatic COVID-19 due to Phe456Leu-containing variants (30·4% [–1·8 to 52·5]). Adverse events occurred in 833 (49·9%) of","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"51 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sipavibart: when a success changes into a failure","authors":"Daniele Focosi, Arturo Casadevall","doi":"10.1016/s1473-3099(24)00812-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00812-0","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"22 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}